Cofoe Medical Technology Co.,Ltd. (ASX: 301087) has disclosed a plan to repurchase a portion of its A-shares through centralized competitive bidding on the exchange.
The repurchased shares are intended to be cancelled in full, leading to a reduction in the company's registered capital.
The total amount of funds allocated for this buyback program is set at no less than 1 billion yuan and no more than 2 billion yuan.
The maximum repurchase price has been established at 69.66 yuan per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.